VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 16, 2010) - TSX VENTURE COMPANIES: AGRITEC SYSTEMS, INC. ("AGR") BULLETIN TYPE: Shares for...
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 8, 2010) - TSX VENTURE COMPANIES BULLETIN TYPE: Cease Trade Order BULLETIN DATE: November 5...
VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 28, 2010) - TSX VENTURE COMPANIES ANGLO SWISS RESOURCES INC. ("ASW") BULLETIN TYPE:...
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 25, 2010) - TSX VENTURE COMPANIES AMARC RESOURCES LTD. ("AHR") BULLETIN TYPE: Private...
WILMINGTON, Del., Feb. 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it provided $769.6 million in savings to...
LONDON, January 28 /PRNewswire-FirstCall/ -- Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David...
WILMINGTON, Del., Jan. 13 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that enrollment and re-enrollment for two of its...
WILMINGTON, Del., Dec. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal...
WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at...
WILMINGTON, Del., Nov. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced it has submitted a New Drug Application (NDA) to the...
Late breaking data from PLATO sub-analysis presented at the American Heart Association Scientific Sessions ORLANDO, Fla., Nov. 15...
New Approach to Treat Opioid-Induced Constipation SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Data from a phase II study demonstrated that oral...
WILMINGTON, Del., Oct. 26 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it will provide free medication to Mercy...
WILMINGTON, Del., Oct. 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the U.S. Food and Drug Administration (FDA...
Significant effects shown with no increase in major bleeding compared to clopidogrel in head-to-head trial SAN FRANCISCO, Sept. 24...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.